4//SEC Filing
Dumas Jacques 4
Accession 0001209191-17-049702
CIK 0001373707other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 4:15 PM ET
Size
6.0 KB
Accession
0001209191-17-049702
Insider Transaction Report
Form 4
Dumas Jacques
Chief ScientificOfficer
Transactions
- Sale
Common Stock
2017-08-17$5.86/sh−7,155$41,928→ 0 total
Footnotes (3)
- [F1]On January 6, 2016, the Reporting person was granted 35,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on June 10, 2016. Of the 2016 RSU grant, 11,667 shares vested on January 6, 2017 of which 4,512 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on the vesting date. The remaining 7,155 shares were sold on August 17, 2017 and such sale is reported on this Form 4.
- [F2]The sale of these shares of common stock reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $5.79 to $5.90 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
TETRAPHASE PHARMACEUTICALS INC
CIK 0001373707
Entity typeother
Related Parties
1- filerCIK 0001598640
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 4:15 PM ET
- Size
- 6.0 KB